BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

357 related articles for article (PubMed ID: 25572548)

  • 1. Anti-TNFs in axial spondyloarthritis.
    Kocijan R; Muschitz C; Rech J
    Wien Med Wochenschr; 2015 Jan; 165(1-2):10-3. PubMed ID: 25572548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor necrosis factor α inhibition in radiographic and nonradiographic axial spondyloarthritis: results from a large observational cohort.
    Ciurea A; Scherer A; Exer P; Bernhard J; Dudler J; Beyeler B; Kissling R; Stekhoven D; Rufibach K; Tamborrini G; Weiss B; Müller R; Nissen MJ; Michel BA; van der Heijde D; Dougados M; Boonen A; Weber U;
    Arthritis Rheum; 2013 Dec; 65(12):3096-106. PubMed ID: 23983141
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adalimumab efficacy in enteropathic spondyloarthritis: A 12-mo observational multidisciplinary study.
    Luchetti MM; Benfaremo D; Ciccia F; Bolognini L; Ciferri M; Farinelli A; Rossini M; Mosca P; Triolo G; Gabrielli A
    World J Gastroenterol; 2017 Oct; 23(39):7139-7149. PubMed ID: 29093622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New evidence on the management of spondyloarthritis.
    Sieper J; Poddubnyy D
    Nat Rev Rheumatol; 2016 May; 12(5):282-95. PubMed ID: 27052489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of Long-Term Etanercept Treatment on Clinical Outcomes and Objective Signs of Inflammation in Early Nonradiographic Axial Spondyloarthritis: 104-Week Results From a Randomized, Placebo-Controlled Study.
    Dougados M; van der Heijde D; Sieper J; Braun J; Citera G; Lenaerts J; van den Bosch F; Wei JC; Pedersen R; Bonin R; Jones H; Marshall L; Logeart I; Vlahos B; Bukowski JF; Maksymowych WP
    Arthritis Care Res (Hoboken); 2017 Oct; 69(10):1590-1598. PubMed ID: 28482137
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of spondyloarthritis beyond TNF-alpha blockade.
    Van den Bosch F; Deodhar A
    Best Pract Res Clin Rheumatol; 2014 Oct; 28(5):819-27. PubMed ID: 25488787
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2018 APLAR axial spondyloarthritis treatment recommendations.
    Tam LS; Wei JC; Aggarwal A; Baek HJ; Cheung PP; Chiowchanwisawakit P; Dans L; Gu J; Hagino N; Kishimoto M; Reyes HM; Soroosh S; Stebbings S; Whittle S; Yeap SS; Lau CS
    Int J Rheum Dis; 2019 Mar; 22(3):340-356. PubMed ID: 30816645
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept for the treatment of non-radiographic axial spondyloarthritis.
    Rios Rodriguez V; Poddubnyy D
    Expert Rev Clin Immunol; 2016; 12(5):493-500. PubMed ID: 26788837
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological management of axial spondyloarthritis in adults.
    Toussirot E
    Expert Opin Pharmacother; 2019 Aug; 20(12):1483-1491. PubMed ID: 31095430
    [No Abstract]   [Full Text] [Related]  

  • 10. [The pharmacotherapy of spondyloarthritis].
    Curković B
    Reumatizam; 2011; 58(2):65-8. PubMed ID: 22232952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Effect of Comedication With a Conventional Synthetic Disease-Modifying Antirheumatic Drug on Drug Retention and Clinical Effectiveness of Anti-Tumor Necrosis Factor Therapy in Patients With Axial Spondyloarthritis.
    Nissen MJ; Ciurea A; Bernhard J; Tamborrini G; Mueller R; Weiss B; Toniolo M; Exer P; Gabay C; Finckh A;
    Arthritis Rheumatol; 2016 Sep; 68(9):2141-50. PubMed ID: 27015429
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disease-modifying Antirheumatic Drugs (DMARD) and Combination Therapy of Conventional DMARD in Patients with Spondyloarthritis and Psoriatic Arthritis with Axial Involvement.
    Simone D; Nowik M; Gremese E; Ferraccioli GF
    J Rheumatol Suppl; 2015 Nov; 93():65-9. PubMed ID: 26523061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Spondyloarthritis: from unifying concepts to improved treatment.
    Paramarta JE; Baeten D
    Rheumatology (Oxford); 2014 Sep; 53(9):1547-59. PubMed ID: 24369419
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BSR and BHPR guideline for the treatment of axial spondyloarthritis (including ankylosing spondylitis) with biologics.
    Hamilton L; Barkham N; Bhalla A; Brittain R; Cook D; Jones G; Mackay K; Marshall D; Marzo-Ortega H; Murphy D; Riddell C; Sengupta R; Siebert S; Van Rossen L; Gaffney K;
    Rheumatology (Oxford); 2017 Feb; 56(2):313-316. PubMed ID: 27558584
    [No Abstract]   [Full Text] [Related]  

  • 15. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The -308 TNFα and the -174 IL-6 promoter polymorphisms associate with effective anti-TNFα treatment in seronegative spondyloarthritis.
    Fabris M; Quartuccio L; Fabro C; Sacco S; Lombardi S; Ramonda R; Biasi D; Punzi D; Adami S; Olivieri I; Curcio F; De Vita S
    Pharmacogenomics J; 2016 Jun; 16(3):238-42. PubMed ID: 26149736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early tumor necrosis factor α antagonist therapy in everyday practice for inflammatory back pain suggesting axial spondyloarthritis: results from a prospective multicenter french cohort.
    Canouï-Poitrine F; Poulain C; Molto A; Le Thuaut A; Lafon C; Farrenq V; Ferkal S; Le Corvoisier P; Ghaleh B; Bastuji-Garin S; Fautrel B; Dougados M; Claudepierre P
    Arthritis Care Res (Hoboken); 2014 Sep; 66(9):1395-402. PubMed ID: 24664935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of serious infections in biological treatment of patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis: a meta-analysis.
    Wang S; He Q; Shuai Z
    Clin Rheumatol; 2018 Feb; 37(2):439-450. PubMed ID: 29290076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis.
    Maksymowych WP; Inman RD; Gladman D; Thomson G; Stone M; Karsh J; Russell AS;
    J Rheumatol; 2003 Jun; 30(6):1356-63. PubMed ID: 12784417
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deciding who to treat with biologic disease-modifying antirheumatic drugs in axial spondyloarthritis.
    Wendling D; Goupille P
    Immunotherapy; 2020 Aug; 12(12):857-860. PubMed ID: 32635788
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 18.